Malignant Neoplasm of Breast Clinical Trial
Official title:
Determination of the Sensitifity of ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes in Breast Cancer - a Monocenter Prospective Open-label Clinical Trial
Objectives of Clinical Trial
The main objective of this clinical trial is to show the efficacy of fluorescence
lymphangiography with indocyanine green (ICG) for the detection of sentinel lymph nodes.
Considering the high diagnostic accuracy and less vulnerable staging and therapy procedures,
SLNB has rapidly become the state of the art diagnostic for axillary staging in early breast
cancer.
Prior surgery, the so called sentinel lymph nodes are detected, harvested and
histopathologically examined. The histopathologic status of the sentinel node thereby
accurately reflects the status of the remaining axillary nodes. The sentinel lymph node
biopsy allows minimizing risks and burdens for patients who very likely have no metastasis
in the axillary lymph nodes sparing the ALND and reducing the risk of surgery and
postoperative lymph oedema for instance. Contrarily to former procedure where an axillary
lymph node dissection (ALND) was done each time, an ALND now only follows if the detected
sentinel lymph node is metastatic.
Routinely sentinel lymph nodes are mapped using radiocolloid tracers such as technetium,
sometimes combined with a blue dye.
However the infrastructure for a radioactive tracing is complex and not available easily:
special techniques and equipment for the manufacturing of the radiocolloid as well as
training in the use with radioisotopes are needed. For example, the application of
radioactive markers needs a ready access to a nuclear medicine department, a pre-operative
visit and an effective coordination between the involved disciplinesis. As these
radioisotopes are formed by specialised, rare industry facilities availability is heavenly
dependend and lack of radioisotopes with shortages in diagnostic procedures has already been
reported. Furthermore radiocolloid mapping is associated with radioactive exposure of the
concerned patients and health workers and imposes problems with surgical waste disposal.
Novel methods for detecting sentinel lymph nodes which waive the pre-operative injection of
the radioactive marker are currently investigated. One of these new methods is the
application of a fluorescence marker for SLN detection.
In this clinical trial a novel method for detecting the sentinel lymph node using
indocyanine green, a fluorescent molecule shall by investigated.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02378337 -
Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality
|
N/A | |
Completed |
NCT01953003 -
Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
|
Phase 3 | |
Enrolling by invitation |
NCT05486520 -
Low-field MRI for Breast Cancer Screening
|
N/A | |
Completed |
NCT05159778 -
Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)
|
Phase 2 | |
Active, not recruiting |
NCT03379428 -
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02891681 -
Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment
|
N/A | |
Withdrawn |
NCT03261323 -
Breast Reconstruction Following Breast Cancer in Very High Risk Patients
|
N/A | |
Recruiting |
NCT04669873 -
Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery
|
N/A | |
Completed |
NCT02408393 -
MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery
|
Phase 3 | |
Completed |
NCT03289819 -
Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC
|
Phase 2 | |
Completed |
NCT02495363 -
Analgesic Effects of Ultrasound Guided PEC Blocks on Analgesic Opioid Consumption of Cancer Surgery Patients
|
||
Completed |
NCT03159195 -
Ibrance Real World Insights
|
||
Completed |
NCT03425656 -
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer
|
Phase 3 | |
Active, not recruiting |
NCT05033756 -
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
|
Phase 2 | |
Not yet recruiting |
NCT01641003 -
Isolation and Characterization of Cancer Stem Cells Using iFP Technique
|
N/A | |
Active, not recruiting |
NCT05364450 -
Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03435952 -
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
|
Phase 1 | |
Active, not recruiting |
NCT02204098 -
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
|
Phase 1 | |
Not yet recruiting |
NCT06251544 -
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02187991 -
Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
|
Phase 2 |